Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DRUP trial of sunitinib for molecularly matched advanced cancers
NL-OMON59656Phase 2Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in Nonhematologic neoplasms, multiple myeloma (MM), non-Hodgkin lymphoma (NHL) and 1 more, sponsored by Netherlands Cancer Institute. Primary endpoints: Percentage of patients treated based on their molecular tumor profile, Objective tumor response and 2 more. Started Jul 2016; status: recruiting.
02
Drugs
sunitinib
03
Conditions
Nonhematologic neoplasmsmultiple myeloma (MM)non-Hodgkin lymphoma (NHL)T-cell prolymphocytic leukemia (T-PLL)
Beyond the preview
Go deeper on NL-OMON59656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59656.